Cleghorn J M, Kaplan R D, Szechtman B, Szechtman H, Brown G M, Franco S
Department of Psychiatry, McMaster University, Hamilton, Ontario.
J Clin Psychiatry. 1991 Jan;52(1):26-30.
The authors compare symptoms and neuropsychological test performance in DSM-III schizophrenic patients who reported prior substance abuse (N = 38) with those in patients who reported no such abuse (N = 25) to determine the impact of substance abuse on the psychopathology of schizophrenia. Positive and negative symptom scores were derived from the Schedule for Affective Disorders and Schizophrenia. Sixty neuropsychological measures drawn from commonly used tests of intelligence, memory, learning, fluency, and problem solving were calculated. Separate analyses were performed on patients in a psychotic episode who were free of neuroleptics (N = 27) and on those taking maintenance neuroleptics (N = 36). Among unmedicated patients, those who reported prior substance abuse had significantly higher thought disorder scores. Among neuroleptic-medicated patients, hallucination and delusion scores were significantly higher in the patients who reported prior substance abuse. The substance abuse followed withdrawal from social relations and preceded the onset of positive symptoms. None of the neuropsychological tests discriminated between abusers and nonabusers.
作者将报告有既往物质滥用史的DSM-III精神分裂症患者(N = 38)与报告无此类滥用史的患者(N = 25)的症状及神经心理学测试表现进行比较,以确定物质滥用对精神分裂症精神病理学的影响。阳性和阴性症状评分来自情感障碍和精神分裂症量表。计算了从常用的智力、记忆、学习、流畅性和问题解决测试中选取的60项神经心理学指标。对未服用抗精神病药物的精神病发作患者(N = 27)和服用维持性抗精神病药物的患者(N = 36)分别进行了分析。在未用药的患者中,报告有既往物质滥用史的患者思维障碍得分显著更高。在服用抗精神病药物的患者中,报告有既往物质滥用史的患者幻觉和妄想得分显著更高。物质滥用发生在社交关系退缩之后、阳性症状出现之前。没有一项神经心理学测试能区分滥用者和非滥用者。